Thomas Paul Rak, MD | |
415 E Home Rd, Springfield, OH 45503-2708 | |
(937) 399-9997 | |
(937) 399-5633 |
Full Name | Thomas Paul Rak |
---|---|
Gender | Male |
Speciality | Plastic And Reconstructive Surgery |
Experience | 26 Years |
Location | 415 E Home Rd, Springfield, Ohio |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124019807 | NPI | - | NPPES |
0207029 | Medicaid | OH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | 35-069331R (Ohio) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Ohio Valley Surgical Hospital | Springfield, OH | Hospital |
Entity Name | Rak Plastic And Reconstructive Surgery Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1053503078 PECOS PAC ID: 3476647900 Enrollment ID: O20070914000346 |
News Archive
A new study in the current issue of Biological Psychiatry suggests that women are particularly susceptible to the pain-relieving placebo effect of vasopressin.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7.
Some believe e-cigarettes are less harmful than smoking tobacco since e-cig vapor doesn't contain the chemicals found in tobacco smoke.
Two years of maintenance therapy with rituximab dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkin's Lymphoma (NHL).
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Thomas Paul Rak, MD 415 E Home Rd, Springfield, OH 45503-2708 Ph: (937) 399-9997 | Thomas Paul Rak, MD 415 E Home Rd, Springfield, OH 45503-2708 Ph: (937) 399-9997 |
News Archive
A new study in the current issue of Biological Psychiatry suggests that women are particularly susceptible to the pain-relieving placebo effect of vasopressin.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7.
Some believe e-cigarettes are less harmful than smoking tobacco since e-cig vapor doesn't contain the chemicals found in tobacco smoke.
Two years of maintenance therapy with rituximab dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkin's Lymphoma (NHL).
› Verified 1 days ago